A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

NCT05099848 | Completed Phase 2 DMC

• 1 other identifier: MA-HCC-II-015
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

The study is being conducted to evaluate the efficacy and safety of conversion treatment of Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib for unresected hepatocellular carcinoma.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma; Camrelizumab; Apatinib; Hepatic artery infusion chemotherapy（HAIC）; Conversion therapy

Outcome Measures

Primary Outcomes (2)

• R0 resection rate

  the complete resection rate of all tumor under microscope

  within 28 working days after operation

• Surgical conversion rate

  Surgical conversion rate was defined as the proportion of subjects with successful conversion over all subjects who received conversion treatment

  within 28 working days after operation

Secondary Outcomes (8)

• MPR

  within 14 working days after operation

• Objective response rate (ORR) by RECIST 1.1 and mRECIST

  From date of first dose of study drug until disease progression, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)

• The disease control rate (DCR)

  From date of first dose of study drug until disease progression, stable disease, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to approximately 3 years)

• Duration of response (DOR) by RECIST 1.1 and mRECIST

  From the first documentation of CR or PR to the first date of documentation of disease progression or death whichever occurs first (up to approximately 3 years)

• The progression-free survival time (PFS)

  From the first documentation of PD to the first date of documentation of disease progression or death whichever occurs first (up to approximately 3 years)

Study Arms (1)

CAHAIC group

EXPERIMENTAL

Hepatic Arterial Infusion Chemotherapy combined with Camrelizumab and Apatinib

Drug: Camrelizumab

Interventions

Camrelizumab DRUG

Procedure: 1. Taking Apatinib-Mesylate Tablets (250 mg/tablet) orally on the 1st day 30minutes after meals, once a day, for continuous medication. 2. On the 2nd day of treatment, intravenous infusion of Camrelizumab 200mg every 3 weeks. 3. On the 3rd to 4th day of treatment, HAIC was conducted through a catheter intubated into the tumor feeding artery under DSA guidance with the following chemotherapeutic drugs (mFOLFOX, oxaliplatin 85 mg/m2 in 0-2 hours, folinic acid 400 mg/m2 in 2-3 hours, 5-FU 2500 mg/m2 46 hours) pumped into the tumor artery. The HAIC is repeated every 3 weeks. The cumulative maximum sessions of HAIC is up to 8 times. The cumulative maximum drug use period is up to 8 cycles. Patient will be administratied radical resection if possible during treatment. The patient is concurrent on medication until the treatment discontinuation criteria specified in the protocol appear.

Also known as: Apatinib, FOLFOX Protocol (Oxaliplatin, fluorouracil, and leucovorin); Camrelizumab for injection and Apatinib-Mesylate Tablets

CAHAIC group

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \- 1. Subjects with hepatocellular carcinoma diagnosed or pathologically diagnosed according to the clinical diagnostic criteria of the diagnosis and treatment of primary liver cancer (2019 edition); 2. Subjects whose BCLC stage is B-C; 3. Subjects whose Child-Pugh is grade A; 4. Subjects whose the ECOG score is 0-1; 5. Subjects without extrahepatic metastases, no diffuse multiple tumors throughout the liver; 6. According to the researcher's assessment, subjects with hepatocellular carcinoma who do not have the conditions for radical resection, but are expected to achieve radical resection after conversion therapy, including but not limited to one of the following situations:
• There are less than 3 tumors and mainly concentrated on the side of the liver;
• Imaging proved to be combined with portal vein tumor thrombus (PVTT);
• The investigator believes that other situations where radical resection may be achieved through conversion therapy.
• \. Subjects whose estimated survival period is more than 3 months; 8. Subjects with at least one measurable lesion (according to the RECIST 1.1 standard, the long diameter of the CT scan of tumor lesions is ≥10mm, and the short diameter of CT scan of lymph node lesions is ≥15mm); 9. Newly treated subjects who have not undergone any local or systemic treatment for tumors in the past, and hepatocellular carcinoma patients who have undergone radical resection before recurrence after 2 years can be included; 10. Subjects' Routine laboratory tests (blood routine, liver and kidney function, coagulation function, etc.) have no significant abnormalities 11. Subjects with potential for childbirth need to use a medically approved contraceptive method (such as intrauterine device, contraceptive pill or condom) during the study treatment period and within 1 month after the end of the study treatment period; and The serum or urine HCG test within 72 hours before study entry must be negative, and it must be a non-lactating period; 12.18-80 years old; 13. Subjects participated in the study voluntarily, without mental illness or other mental symptoms, with full civil capacity, signed informed consent, good compliance, and able to cooperate with follow-up.

You may not qualify if:

• \- 1. Previously diagnosed by histology/cytology with fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components; 2. A history of hepatic encephalopathy, or a history of liver transplantation; 3. A history of allergies to test drugs: Camrelizumab and any component of other drugs; 4. The subject's refractory pleural or pericardial effusion is poorly controlled; 5. Previously received anti-PD-1 or PD-L1 or CTLA-4 or Car-T immunotherapy; 6. Except for history of interstitial lung disease (radiation pneumonia that has not been treated with hormones), history of non-infectious pneumonia; 7. The subject has any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis , Nephritis, hyperthyroidism, reduced thyroid function; subjects suffering from vitiligo or asthma in childhood has completely resolved, and no intervention after adults can be included; subjects with asthma requiring bronchodilators for medical intervention can not be included ); 8. The subject is using immunosuppressive agents, or systemic or absorbable local hormone therapy to achieve immunosuppressive purposes (dose\>10mg/day prednisone or other curative hormones), and within 2 weeks before enrollment Still in use; 9. Severe infections (CTCAE\> level 2) occurred 4 weeks before the first use of the study drug; 10. The subject has experienced acute cardiovascular and cerebrovascular diseases such as acute cerebral infarction, acute coronary syndrome, etc. and the cardiovascular clinical symptoms or diseases within one month are not well controlled; 11. According to NYHA standards, grade Ⅲ to Ⅳ cardiac insufficiency, or cardiac color Doppler ultrasound examination reveals that the left ventricular ejection fraction (LVEF) is less than 50%; 12. Patients with a clear gastrointestinal bleeding tendency, including the following conditions: local active ulcer lesions, and fecal occult blood {(＋＋) can not be included in the group}; patients with a history of melena and hematemesis within 2 months; 13. Abnormal blood coagulation function (INR\>1.5APTT\>1.5ULN), with bleeding tendency; 14. Long-term unhealed wounds or fractures; major surgical operations or severe traumatic injuries, fractures or ulcers occurred within 4 weeks; 15. Subjects with congenital or acquired immune deficiencies (such as HIV infection), or active hepatitis (hepatitis B reference: HBV DNA test value exceeding 2000 IU/ml) need to be excluded; if the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA\<2000 IU/mL, and received anti-HBV therapy for at least 14 days before randomization and is willing to receive antiviral therapy throughout the study period (recommended nucleoside analogs, such as entecavir or alternative Norfovir dipivoxil, etc.) can be included in the study.

Sponsors & Collaborators

• Shandong Cancer Hospital and Institute: lead
• Jiangsu HengRui Medicine Co., Ltd.: collaborator

Study Sites (1)

Shandong Cancer Hospital and Institute

Jinan, Shandong, 250117, China

Location

Related Publications (1)

• Yalikun K, Li Z, Zhang J, Chang Z, Li M, Sun Z, Liu Z, Yang Y, Xu L, Li L, Zhang C, Sun P, Zhong J, Cui K, Shi X, Zhang B, Zhao L. Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial. BMC Cancer. 2025 May 7;25(1):838. doi: 10.1186/s12885-025-14250-5.

  PMID: 40335980 DERIVED

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

camrelizumab; apatinib; Folfox protocol; Oxaliplatin; Fluorouracil; Leucovorin; Injections

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Uracil; Pyrimidinones; Pyrimidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Coenzymes; Enzymes and Coenzymes; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Lei Zhao, MD

  Shandong Cancer Hospital and Institute

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor; Director

Study Record Dates

• First Submitted: October 13, 2021
• First Posted: October 29, 2021
• Study Start: March 17, 2021
• Primary Completion: January 31, 2024
• Study Completion: May 31, 2024
• Last Updated: May 22, 2026

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)